Lazuriton Nano Biotechnology 10-K 13 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Lazuriton Nano Biotechnology (U.S.A.) Inc.
Entity Central Index Key	1,666,178
Trading Symbol	lnbi
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding	0
Entity Public Float		$ 0
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

BALANCE SHEET

BALANCE SHEET - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 100,928	$ 10,191
Total current assets	100,928	10,191
Total Assets	100,928	10,191
Current Liabilities
Accrued expenses	5,680
Due to related parties	223,631	80,207
Total current liabilities	229,311	80,207
Total Liabilities	229,311	80,207
Stockholders' Deficit
Common stock, $0.0001 par value; 750,000,000 shares authorized, 60,000,000 shares issued and outstanding	6,000	6,000
Additional paid-in capital	54,000	54,000
Accumulated deficits	(188,383)	(130,016)
Total stockholders' deficit	(128,383)	(70,016)
Total Liabilities and Stockholders' Deficit	$ 100,928	$ 10,191

BALANCE SHEET (Parentheticals)

BALANCE SHEET (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	60,000,000	60,000,000
Common stock, shares outstanding	60,000,000	60,000,000

STATEMENT OF OPERATIONS

STATEMENT OF OPERATIONS - USD ($)	7 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016
Income Statement [Abstract]
Net revenue
General and administrative expenses	130,016	58,382
Loss from operations	(130,016)	(58,382)
Other income (expenses)
Interest income	0	15
Total other income (expenses)	0	15
Loss before income taxes	(130,016)	(58,367)
Provision for income taxes
Net loss	$ (130,016)	$ (58,367)
Weighted Average Shares Outstanding:
Basic and diluted (in shares)	14,655,352	60,000,000
Net loss per share
Basic and diluted (in dollars per share)	$ (0.01)	$ 0

STATEMENT OF CASH FLOWS

STATEMENT OF CASH FLOWS - USD ($)	7 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016
Cash Flows from Operating Activities
Net loss	$ (130,016)	$ (58,367)
Changes in assets and liabilities:
Increase in accrued expenses		5,680
Increase in due to related parties	80,207	143,424
Net cash provided by (used in) operating activities	(49,809)	90,737
Cash Flows from Financing Activities
Issuance of common stock	60,000
Net cash provided by financing activities	60,000
Net increase in cash and cash equivalents	10,191	90,737
Cash and Cash Equivalents
Beginning		10,191
Ending	10,191	100,928
Cash paid during the year for:
Interest
Income taxes

STATEMENTS OF SHAREHOLDERS' DEF

STATEMENTS OF SHAREHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jun. 01, 2015
Balance (in shares) at Jun. 01, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for cash (June 4, 2015)	$ 1	$ 9		$ 10
Common stock issued for cash (November 10, 2015)	$ 5,999	$ 53,991		$ 59,990
Common stock issued for cash (in shares) (June 4, 2015)	10,000
Common stock issued for cash (in shares) (November 10, 2015)	59,990,000
Net loss for the period			$ (130,016)	$ (130,016)
Net loss for the period (June 4, 2015)
Net loss for the period (November 10, 2015)
Ending at Dec. 31, 2015	$ 6,000	54,000	(130,016)	$ (70,016)
Ending (in shares) at Dec. 31, 2015	60,000,000			60,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss for the period			(58,367)	$ (58,367)
Ending at Dec. 31, 2016	$ 6,000	$ 54,000	$ (188,383)	$ (128,383)
Ending (in shares) at Dec. 31, 2016	60,000,000			60,000,000

ORGANIZATION AND BUSINESS

ORGANIZATION AND BUSINESS	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS	NOTE 1. ORGANIZATION AND BUSINESS Lazuriton Nano Biotechnology (U.S.A.) Inc. (the “Company”) was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products. The Company’s year-end is December 31.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2016
Going Concern [Abstract]
GOING CONCERN	NOTE 2. GOING CONCERN These financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company had an accumulated deficit of $188,383 and $130,016 as of December 31, 2016 and 2015, respectively, and it had no revenue from operations. The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty. The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, its president and a member of our board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements and related notes have been prepared in conformity with accounting principles generally accepted in the United States of America. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Reclassification Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit. Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less. Net Income (loss) per Share Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At December 31, 2016 and 2015, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized. Recent Accounting Pronouncements In June 2014, the FASB issued Accounting Standards Updated No. 2014-10, "Development Stage Entities” (“ASU 2014-10”) which removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the update eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and shareholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. During the year ended December 31, 2015, the Company has elected to adopt ASU 2014-10. The adoption of this ASU allowed the Company to remove the inception to date information and all references to development stage.

DUE TO RELATED PARTIES

DUE TO RELATED PARTIES	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
DUE TO RELATED PARTIES	NOTE 4. DUE TO RELATED PARTIES The Company has advanced funds from its officer and shareholder for working capital purposes. As of December 31, 2016 and 2015, there were $223,631 and $80,207 advances outstanding. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 5. INCOME TAXES As of December 31, 2016, the Company had net operating loss carry forwards of approximately $188,383 that may be available to reduce future years’ taxable income through 2036. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following: For the Years Ended December 31, 2016 2015 Federal income tax benefit attributable to: Current Operations $ 19,845 $ 44,205 Less: valuation allowance (19,845 ) (44,205 ) Net provision for Federal income taxes $ - $ - The tax effects of temporary differences and carry forwards that give rise to significant portions of deferred tax assets and liabilities consist of the following: December 31, December 31, Deferred tax asset attributable to: Net operating loss carryover $ 64,050 $ 44,205 Less: valuation allowance (64,050 ) (44,205 ) Net deferred tax asset $ - $ - The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below: 2016 2015 Statutory tax benefit (34 )% (34 )% Permanent items - - Change in deferred tax asset valuation allowance 34 34 Provision for income taxes - % - % For the year ended December 31, 2016 and 2015, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

STOCKHOLDER'S DEFICIT

STOCKHOLDER'S DEFICIT	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
STOCKHOLDER'S DEFICIT	NOTE 6. STOCKHOLDER’S DEFICIT On June 4, 2015, the Company has issued 10,000 shares of its $0.0001 par value common stock at a purchase price of $0.001 per share in a total amount of $10 from one shareholder. On November 10, 2015, the Company has issued 59,990,000 shares of its $0.0001 par value common stock shares at a purchase price of $0.001 per share in a total amount of $59,990 from forty-five shareholders.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 7. SUBSEQUENT EVENTS The Company evaluated all events or transactions that occurred after December 31, 2016 up through the date the Company issued these financial statements.

SUMMARY OF SIGNIFICANT ACCOUN14

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements and related notes have been prepared in conformity with accounting principles generally accepted in the United States of America.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification	Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Net Income (loss) per Share	Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At December 31, 2016 and 2015, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2014, the FASB issued Accounting Standards Updated No. 2014-10, "Development Stage Entities” (“ASU 2014-10”) which removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the update eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and shareholders’ equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. During the year ended December 31, 2015, the Company has elected to adopt ASU 2014-10. The adoption of this ASU allowed the Company to remove the inception to date information and all references to development stage.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of provision for Federal income tax	For the Years Ended December 31, 2016 2015 Federal income tax benefit attributable to: Current Operations $ 19,845 $ 44,205 Less: valuation allowance (19,845 ) (44,205 ) Net provision for Federal income taxes $ - $ -
Schedule of tax effects of temporary differences and carryforwards	December 31, December 31, Deferred tax asset attributable to: Net operating loss carryover $ 64,050 $ 44,205 Less: valuation allowance (64,050 ) (44,205 ) Net deferred tax asset $ - $ -
Schedule of provision for income taxes on loss before taxes	2016 2015 Statutory tax benefit (34 )% (34 )% Permanent items - - Change in deferred tax asset valuation allowance 34 34 Provision for income taxes - % - %

GOING CONCERN (Detail Textuals)

GOING CONCERN (Detail Textuals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficits	$ (188,383)	$ (130,016)

DUE TO RELATED PARTIES (Detail

DUE TO RELATED PARTIES (Detail Textuals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Due to related parties	$ 223,631	$ 80,207
Percentage of interest rates on advances outstanding	0.00%

INCOME TAXES - Summary of provi

INCOME TAXES - Summary of provision for Federal income tax (Details) - USD ($)	7 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016
Federal income tax benefit attributable to:
Current Operations	$ 44,205	$ 19,845
Less: valuation allowance	(44,205)	(19,845)
Net provision for Federal income taxes

INCOME TAXES - Summary of tax e

INCOME TAXES - Summary of tax effects of temporary differences and carryforwards (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax asset attributable to:
Net operating loss carryover	$ 64,050	$ 44,205
Less: valuation allowance	(64,050)	(44,205)
Net deferred tax asset

INCOME TAXES - Summary of diffe

INCOME TAXES - Summary of difference between effective rate reflected in provision for income taxes (Details 2)	7 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory tax benefit	(34.00%)	(34.00%)
Permanent items
Change in deferred tax asset valuation allowance	34.00%	34.00%
Provision for income taxes

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals)	Dec. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 188,383

STOCKHOLDER'S DEFICIT (Detail T

STOCKHOLDER'S DEFICIT (Detail Textuals)	7 Months Ended
	Dec. 31, 2015USD ($)Shareholders$ / sharesshares	Dec. 31, 2016$ / shares
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
June 4, 2015
Common stock issued for cash | $	$ 10
Common stock issued for cash (in shares) | shares
Common stock, par value (in dollars per share)	$ 0.0001
Sale of stock, price per share	$ 0.001
Number of shareholder | Shareholders	1
November 10, 2015
Common stock issued for cash | $	$ 59,990
Common stock issued for cash (in shares) | shares
Common stock, par value (in dollars per share)	$ 0.0001
Sale of stock, price per share	$ 0.001
Number of shareholder | Shareholders	45
Common Stock | June 4, 2015
Common stock issued for cash | $	$ 1
Common stock issued for cash (in shares) | shares	10,000
Common Stock | November 10, 2015
Common stock issued for cash | $	$ 5,999
Common stock issued for cash (in shares) | shares	59,990,000